![]() | Up a level |
Banerjee, Susana ORCID: 0000-0002-8840-7934, Michalarea, Vasiliki
ORCID: 0000-0002-3102-3534, Ang, Joo Ern
ORCID: 0000-0003-2103-996X, Ingles Garces, Alvaro
ORCID: 0000-0002-0073-4237, Biondo, Andrea
ORCID: 0000-0003-0599-254X, Funingana, Ionut-Gabriel
ORCID: 0000-0002-1197-2652, Little, Martin
ORCID: 0000-0003-2592-1570, Ruddle, Ruth
ORCID: 0000-0003-0025-8872, Raynaud, Florence
ORCID: 0000-0003-0957-6279, Riisnaes, Ruth
ORCID: 0000-0002-8924-302X et al (show 19 more authors)
(2022)
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, 28 (21).
pp. 4634-4641.